The preclinical pancreatic cancer murine model testing of rS1-mmGMCSF expressing murine GM-CSF showed the systemic improvement in immune cells (DC and T cell) antitumoral activity (175). This evidence concerns the gene CSF2 and familial pancreatic carcinoma.